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AbstrACt
Introduction Because of their high risk of stroke, 
anticoagulation therapy is recommended for most patients 
with atrial fibrillation (AF). The present study evaluated the 
use of anticoagulants in the community and in a hospital 
setting for patients with AF and its associations with stroke.
Methods Patients admitted with stroke to four major 
hospitals in County of Surrey, England were surveyed in 
the 2014–2016 Sentinel Stroke National Audit Programme. 
Descriptive statistics was used to summarise subject 
characteristics and χ² test to assess differences between 
categorical variables.
results A total of 3309 patients, 1656 men (mean age: 
73.1 years±SD 13.2) and 1653 women (79.3 years±13.0) 
were admitted with stroke (83.3% with ischaemic, 15.7% 
haemorrhagic stroke and 1% unspecified). AF occurred more 
frequently (χ2=62.4; p<0.001) among patients admitted 
with recurrent (30.2%) rather than with first stroke (17.1%). 
There were 666 (20.1%) patients admitted with a history 
of AF, among whom 304 (45.3%) were anticoagulated, 279 
(41.9%) were untreated and 85 (12.8%) deemed unsuitable 
for anticoagulation. Of the 453 patients with history of AF 
admitted with a first ischaemic stroke, 138 (37.2%) were on 
anticoagulation and 41 (49.6%) were not (χ2 = 6.3; p<0.043) 
and thrombolysis was given more frequently for those without 
prior anticoagulation treatment (16.1%) or unsuitable for 
anticoagulation (23.6%) compared with those already on 
anticoagulation treatment (8.3%; χ2=10.0; p=0.007). Of 
2643 patients without a previous history of AF, 171 (6.5%) 
were identified with AF during hospitalisation. Of patients 
with AF who presented with ischaemic stroke who were not 
anticoagulated or deemed unsuitable for anticoagulation 
prior to admission, 91.8% and 75.0%, respectively, were 
anticoagulated on discharge.
Conclusions The study highlights an existing burden for 
patients with stroke and reflects inadequate treatment of 
AF which results in an increased stroke burden. There is 
significant scope to improve the rates of anticoagulation.
IntroduCtIon 
Stroke is the second leading cause of death 
in the world, affecting about 6.7 million cases 
per annum (11.9% of all deaths).1 Physical 
disability and cognitive impairment including 
dementia arising from stroke are common2–4 
and have profound effects on patients and 
their carers. These include a high burden of 
care,5 stress and strain6 and depression,7 and 
all impose enormous pressure on social and 
healthcare systems.8 9 There are a number 
of risk factors for stroke including older 
age, hypertension, diabetes, previous stroke 
or transient ischaemic attack (TIA), heart 
diseases including coronary heart disease, 
cardiomyopathy and heart failure, while 
atrial fibrillation (AF) is the greatest risk 
factor, raising the risk of ischaemic stroke by 
fivefold.10–12 
Both AF and stroke are ageing-related 
conditions and it is crucial that AF is detected 
and treated early to prevent stroke. Since the 
1980s numerous clinical trials have examined 
the effectiveness of antithrombotic agents 
such as warfarin and antiplatelet agents 
(aspirin and dipyridamole). A meta-analysis 
strengths and limitations of this study
 ► The strengths of the present study include its sta-
ble and relatively large homogenous cohort of pa-
tients derived from one of the largest NHS regions 
in England.
 ► The data were meticulously collected with few 
missing data by healthcare providers for the pa-
tients using national Sentinel Stroke National Audit 
Programme (SSNAP) protocol.
 ► Although data are derived only from Surrey, it is 
likely to be representative nationally as stroke prev-
alence and characteristics are similar to those pre-
sented in the SSNAP report.
 ► Limitations in the present study include the lack 
of information to explain the reasons for not anti-
coagulating patients with atrial fibrillation in the 
community.
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showed that warfarin treatment for AF reduced the risk 
of stroke by 64% while antiplatelet agents reduced it by 
22%.13 Analysis of pooled data from five randomised 
controlled trials11 showed that warfarin treatment consis-
tently reduced the risk of embolic stroke by 60%–84% 
while the risk of major bleeding was only marginally 
different from controls or those treated with aspirin 
(1.3% vs 1.0%). The efficacy of aspirin was variable across 
the five studies showing risk reduction of 18% with low 
dose (75 mg/day) and with higher dose (325 mg/day). As 
such, modern guidelines do not recommend the use of 
Aspirin or antiplatelet agents as adequate stroke preven-
tion strategy in patients with underlying non-valvular 
AF.14–16 Based on evidence from previous clinical trials, 
anticoagulation by warfarin or non-vitamin K antagonist 
oral anticoagulants (novel oral anticoagulants) have been 
favourably recommended for routine treatment of AF over 
the past three decades.15–18 However, there is evidence 
of undertreatment of AF in the community19–21 which 
associates with increased risk of nosocomial pneumonia, 
prolonged stay in hyperacute stroke units, disability on 
discharge and inpatient mortality.22
The present study evaluated the use of anticoagulation 
in patients with AF and its implications on the develop-
ment of stroke in the County of Surrey, England.
Methods
study design, participants and setting
We conducted a cross-sectional study using data from 
the Sentinel Stroke National Audit Programme (SSNAP) 
which is the registry-based study launched in 2012 by 
the Intercollegiate Stroke Working Party, collecting all 
data submitted by sites via a web-based tool.14 The results 
reflect the organisation of stroke services and contains 
national and site level figures to allow benchmarking 
of performance over time and comparisons between 
regions. SSNAP targets the participating stroke teams, 
medical directors, managers and trust executives.14
We used an anonymised extract of a total of 3309 patients 
admitted to four hyperacute stroke units in the County of 
Surrey (one of the largest National Health Service regions 
in England).22 The sites which included Ashford and St 
Peter’s (n=1038), Frimley Park (n=1010), Royal Surrey 
County (n=612) and Epsom General (n=649) hospitals, 
were surveyed between January 2014 and February 2016. 
Twenty-four patients were admitted multiple times and 
therefore data from their first admission were used for 
analysis. This study population was relatively homoge-
nous and stable, comprising 92.1% white Caucasians, 
6.8% Asian, Black, mixed race and other ethnic popula-
tions and 1.2% not stated.
SSNAP has approval from the Confidentiality Advi-
sory Group of the Health Research Authority to collect 
patient data under section 251 of the National Health 
Service Act 2006. No additional ethical approval was 
sought.
Patient and public involvement
Development of the importance of this research ques-
tion was discussed with the UK national charity for stroke 
victims, Different Strokes. The design, recruitment, anal-
yses and conclusions however were conducted by the inves-
tigators alone. Results of this study will be disseminated to 
participants by presentation at our local meetings.
data recording
All four study centres participated in SSNAP and there-
fore used an identical protocols and data collection 
methodology (available on request). Information on 
sociodemographic (age at arrival, sex and ethnicity) and 
clinical factors as well as investigations were collected 
on an admission proforma. History of AF, hypertension, 
diabetes mellitus and congestive cardiac failure, regular 
medications including antiplatelets and anticoagulants 
was recorded from clinical history, notes review and family 
doctor records. The look-back period was not fixed for all 
the patients. In addition, details of new-onset AF cases, 
defined by presence of AF in two consecutive 12-lead 
recordings by electrocardiography, treatment from the 
point of admission to discharge including anticoagula-
tion and thrombolysis were documented by stroke team 
comprising consultants and stroke nurse specialists.
diagnosis of stroke
Stroke is defined as a clinical syndrome, of presumed 
vascular origin, typified by rapidly developing signs of 
focal or global disturbance of cerebral functions lasting 
more than 24 hours. As for the largest amount of litera-
ture in stroke, the diagnosis of stroke was based on clin-
ical experience with the support of neuroimaging when 
necessary. All stroke specialists involved in our study 
were fully trained stroke physicians according to the UK 
National criteria.23 Ischaemic stroke was defined as stroke 
caused by a blocked artery and haemorrhagic stroke as a 
bleed on the brain caused by a ruptured artery.14 Patients 
considered to have a first stroke were those without a 
previous history of stroke, while those considered with 
recurrent stroke were patients with a recorded previous 
history of stroke.
stroke risk calculations
The risk of stroke in patients with AF was calculated using 
CHADS2 (congestive heart failure=1, hypertension=1, age 
≥75 years=1, stroke/TIA=2) scoring system with a range 
of 0–6 points. CHADS2 scores were categorise into three 
groups of 0, 1 and ≥2 points for analysis in the present 
study.
statistical analysis
The frequency of patients with AF using anticoagulation 
before developing an ischaemic or haemorrhagic stroke 
was assessed by cross tabulation and χ2 tests. Most vari-
ables had no missing data, except for information on type 
of stroke (1%), which were handled in analysis using a 
‘listwise deletion of missing data’ approach. Age data are 
mean ±SD and differences between sexes used a Student’s 
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t-test. Analyses were performed using SPSS V.22.0 (SPSS, 
Chicago, Illinois, USA). The null hypothesis was rejected 
when p<0.05.
results
On admission, the proportions of male and female 
patients were the same. The average age for onset of a 
first stroke was 6.1 years (95% CI 5.2 to 7.0) earlier in men 
than in women (p<0.001). There were 76.9% of patients 
who presented with a first stroke and 23.1% with a recur-
rent stroke. Of the total number of strokes, 83.3% had 
ischaemic and 15.7% with haemorrhagic stroke and 1% 
were unspecified. Thrombolysis was performed in 13.6% 
of those with an ischaemic stroke. During the period of 
admission, 171 of the 2643 patients (6.5%) who had no 
previous history of AF were identified with new onset AF 
(figure 1). On discharge, 88.8% of patients with AF were 
anticoagulated (table 1 and figure 2).
Of those presenting with a first stroke, 1288 were men 
(72.3±13.5 years) and 1255 women (78.3±13.6 years); 
of those with a recurrent stroke, there were 368 men 
(76.3±11.6 years) and 398 women (82.3±10.5 years)—
table 2. The proportion of patients with a history of AF was 
higher (χ2=62.3, p<0.001) among patients who presented 
with recurrent stroke (30.0%) than those presenting with 
first stroke (17.1%).
Of the 666 (20.1%) patients with stroke with a history 
of AF (table 3), 435 had an ischaemic stroke and 231 a 
haemorrhagic stroke. For the patients with an ischaemic 
stroke with AF, 41.6% were being treated in the commu-
nity with an anticoagulant, 45.7% were not being treated 
and 12.6% were deemed unsuitable for anticoagulation, 
that is, those who were known to have AF and for some 
reason or another, were not considered for anticoagulant 
treatment in the community. For those admitted with a 
haemorrhagic stroke, the corresponding proportions 
were 52.4, 34.6% and 13.0%. The proportion of patients 
with haemorrhagic stroke treated with anticoagulants was 
significantly greater. During hospitalisation, 283 with a 
history of AF or new AF had died.
The distributions of patients with AF who were treated 
with an anticoagulant or with antiplatelet are shown in 
a stacked bar chart (figure 3). Among 302 patients with 
AF who were treated with an anticoagulant, 25% were 
on antiplatelet treatment. The proportions of patients 
treated with an antiplatelet rose to 59% and 61% among 
279 patients with AF who were not treated with an anti-
coagulant and 85 patients with AF who were deemed not 
suitable for anticoagulation, respectively.
The proportion of patients who were anticoagulated 
prior to admission was significantly (p<0.05) lower for 
first ischaemic strokes (37.2%) than recurrent ischaemic 
strokes (47.7%). Because there were similar proportions 
Figure 1 Flowchart of the patient cohort investigated in this study. AF, atrial fibrillation. 
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of patients with first and recurrent ischaemic stroke who 
were deemed not suitable for anticoagulation (13.2% vs 
13.0%), an alternative statement is that for those patients 
with ischaemic stroke who were not coagulated a higher 
proportion where in the first compared with recurrent 
stroke cohorts (49.6% vs 39.4%, χ2=6.3, p=0.043). Throm-
bolysis at admission was more frequently used for those 
without prior anticoagulation treatment (15.8%) or 
unsuitable for anticoagulation (20.0%) compared with 
those who were anticoagulated in the community (9.3%; 
χ2=9.0, p=0.011).
On admission, of the 146 patients (43.6%) with AF who 
were treated with being treated with anticoagulants, seven 
patients (−4.8%) discontinued on discharge (figure 2). Of 
the 159 patients who presented with an ischaemic stroke 
with AF and who were not being treated with anticoagu-
lants on admission, 146 (91.8%) were anticoagulated on 
discharge. Of the 40 patients with AF who were deemed 
unsuitable for anticoagulation, 30 (75.0%) were anticoag-
ulated on discharge.
Overall, 315 out of 335 (94.0%) patients with an isch-
aemic stroke with AF were anticoagulated on discharge, 
Table 1 Distribution of 3309 patients, 1656 men and 1653 women admitted with stroke to hospitals in Surrey between 
January 2014 and February 2016
N Proportion (%)
On admission
  Men (73.1±13.2 years):Women (79.3±13.0 years) 1656:1653 50.0:50.0
  First stroke/TIA:Recurrent stroke/TIA 2543:766 76.9:23.1
  Ischaemic stroke:Haemorrhagic stroke 2758:518 83.3:15.7
  Ischaemic stroke thrombolysis
  Yes:No:Not suitable
441:2:2856 13.6:0.1:86.3
History of AF and anticoagulation and antiplatelet status
  History of AF:No history of AF 666:2643 20.1:79.9
  Anticoagulant treatment status of patients with AF history—Yes:No:Not suitable 302:279:85 45.3:41.9:12.8
  Antiplatelet treatment status of patients with AF history—Yes:No:Not suitable 274:320:72 41.1:40.0:10.8
  CHADS2 score in patients with history of AF
   0 30 4.5
   1 148 22.2
   2 200 30.0
   3 121 18.2
   4 125 18.8
   5 37 5.6
   6 5 0.8
   ≥2 488 73.3
Inpatient
  New AF:No previous history 171:2643 6.5
On discharge
  All patients with stroke
  Patients with AF on discharge 554 16.7
  Anticoagulation for AF on discharge 492 88.8
  No anticoagulation for AF on discharge 1 0.2
  Anticoagulation not suitable for AF 61 11.0
  Patients with ischaemic stroke only
  Patients with AF on discharge 501 18.2
  No anticoagulation for AF on discharge 1 0.2
  Anticoagulation for AF on discharge 460 91.8
  Anticoagulation not suitable for AF 40 8.0
All data were complete except a diagnosis of ischaemic or haemorrhagic stroke in 33 (1.0%) patients. 
AF, atrial fibrillation; CHADS2, congestive heart failure, hypertension, age, stroke/TIA; TIA, transient ischaemic attack.
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that is, more than double the proportion of patients with 
AF who were being anticoagulated on admission.
Table 4 shows anticoagulation status in patients with 
AF prior to admission and on discharge according age, 
sex and CHADS2 scores. Anticoagulant treatment range 
between 43% and 50% of patients on admission for all 
age groups, males and females and CHADS2 scores 1 
or ≥2. Anticoagulant treatment was provided in 13% of 
those with CHADS2 score 0 prior to admission. These 
figures rose to between 87% and 97% of patients with AF 
on discharge.
dIsCussIon
We show that about a fifth of patients admitted with a 
stroke to Surrey Hospitals between 2014 and 2016 had 
AF, among whom more than half (54.7%) were untreated 
with or deemed unsuitable for anticoagulant therapy. 
AF occurred more often among patients admitted with 
recurrent stroke (30.2%) than first stroke (17.1%). 
Thrombolysis was carried out more frequently in those 
without previous anticoagulation or unsuitable for anti-
coagulation compared with those who were already 
anticoagulated. New AF was identified after admission 
in 6.5% of those who were not known to have history of 
arrhythmia. More than 90% of patients with AF who were 
not previously treated with and three-quarters of those 
who were deemed unsuitable for anticoagulation in the 
community were anticoagulated on discharge.
The relatively high proportions of patients with AF who 
were previously untreated (45.7%) with an anticoagulant 
in the present study are consistent with findings from 
other studies. Go et al found that only 62% of patients 
with AF who were eligible for warfarin actually received 
the drug.12 Similarly, a review by Darkow et al of health-
care claims for about four million members of an organi-
sation revealed that 61% of patients with AF were suitable 
for anticoagulation but only 39% had started treatment.24 
Our study extended to the analysis of changes in antico-
agulation from the point of admission to discharge in UK 
population. The missed opportunity for AF treatment 
exposes many patients to increased risk of stroke. Anal-
ysis of CHADS2 score in relation to anticoagulation status 
among patients with AF in the community (43%–50%) 
and on discharge (87%–97%) further affirms our find-
ings of unnecessary undertreatment with an anticoagu-
lant, particularly those at highest risk of stroke (CHADS2 
score≥2).
The reasons to explain the lack of anticoagulation 
of patients with AF are likely to depend heavily on the 
characteristics of patients and healthcare providers and 
the interactions between them. Studies have shown poor 
awareness of AF by patients, with only 49% of those with 
the condition could name their condition and only about 
a half knew about the risk of thromboembolism from AF.25 
Lack of access or awareness of the availability or healthcare 
may exist particularly among ethnic minority groups26 or 
those of lower socioeconomic status.26 27 Other reasons 
may be a delay for seeing specialists for assessment before 
Figure 2 Patients admitted with ischaemic stroke and AF 
(n=345) who had their anticoagulation status changed (group 
differences: χ2=16.2, p<0.001). Numbers of patients with AF 
according to anticoagulation status on admission are shown 
in parentheses. AF, atrial fibrillation. 
Table 2 Distribution of 3309 patients with first stroke or recurrent stroke and any history of AF according to sex and previous 
history of stroke, admitted to hospitals in Surrey between January 2014 and February 2016
Patients presented with first 
stroke (n=2543)
Patients presented with 
recurrent stroke (n=766)
χ² test for group 
differences
N Proportion (%) N Proportion (%) χ2 P values
Sex (male:female) 1288:1255 50.6:49.4 368:398 48.0:52.0 1.0 0.206
History of AF admitted with ischaemic 
stroke
371 17.5 193 30.4 50.1 <0.001
History of AF admitted with 
haemorrhagic stroke
61 15.6 38 30.2 13.1 <0.001
History of AF admitted with ischaemic or 
haemorrhagic stroke
435* 17.1 231* 30.2 62.4 <0.001
*Information on type of stroke was not specified in three cases.
AF, atrial fibrillation.
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commencing anticoagulation. It is therefore important to 
disseminate information to the public improve awareness 
of AF and its clinical implications. A study of patients with 
AF showed that the use of an ‘audiobooklet decision aid’ 
improved their understanding of the benefits: risks ratio 
of different treatment options and definitive treatment 
choices.27
The strengths of the present study include its stable 
and relatively large homogenous cohort of patients 
derived from one of the largest NHS regions in England 
which is likely to be nationally representative as indi-
cated by their similar characteristics to those presented 
from national SSNAP data.28 The data were meticulously 
collected with few missing data by healthcare providers 
for the patients using national SSNAP protocol. It would 
be of interest to assess the association of atrial flutter and 
anticoagulation in stroke. Although there is a paucity 
in published data on anticoagulant treatment of atrial 
flutter and the risk of stroke, a recent systematic review 
by Vadmann et al29 suggested that this condition is associ-
ated with increased risk of thromboembolic events. Infor-
mation of atrial flutter was not included in the SSNAP 
protocol and therefore it is likely that our study underes-
timates the association between AF and stroke risk since 
the proportion of atrial flutter is 16.1% compared with 
83.9% of AF in general population.30 Further prospective 
studies are needed to elucidate the risk and effectiveness 
of treatment, including anticoagulation, of atrial flutter 
and stroke outcomes. We did not have information on 
vascular disease and therefore CHA2DS2VASc score could 
not be calculated. We believe that CHADS2 score provides 
adequate information for our purpose in the present 
study. Limitations in the present study include the lack of 
information on type of AF, anticoagulants, thromboem-
bolic and bleeding risk factors and reasons for not anti-
coagulating patients with AF in the community. Patients’ 
preference may account for a small proportion who were 
not treated with anticoagulation. In addition, existing 
contraindications such as risk of falls, history of serious 
haemorrhage or an adverse reaction to anticoagulants 
would make some patients unsuitable for anticoagulation. 
However, after thorough risk assessment, a substantial 
number of patients in the present study who were previ-
ously untreated or deemed unsuitable for anticoagula-
tion treatment in the community were in fact discharged 
from hospital on anticoagulation therapy, 92% and 75%, 
respectively. This difference may reflect the reluctance 
Table 3 Anticoagulation status of 666 patients with a known history of AF who developed either a first stroke or a recurrent 
stroke
Anticoagulation status on admission for patients with 
history of AF Group differences
Yes (n=302) No (n=279) Not suitable (n=85)
χ2 P valuesn % N % N %
All stroke with AF (n=666)
  Ischaemic (n=435) 181 41.6 199 45.7 55 12.6 32.6 <0.001 
  Haemorrhagic (n=231) 121 52.4 80 34.6 30 13.0
First stroke with AF (n=432)*
  Ischaemic (n=371) 138 37.2† 184 49.6† 49 13.2 20.0 <0.001
  Haemorrhagic (n=61) 41 67.2 14 23.0 6 9.8
Recurrent stroke with AF (n=228)*
  Ischaemic (n=90) 92 47.7† 76 39.4† 22 13.0 12.6 0.002
  Haemorrhagic (n=38) 29 76.3 4 10.0 5 12.5
Thrombolysis of ischaemic stroke (n=89) 28 9.3 44 15.8 17 20.0 9.0 0.011
*Information on type of stroke was not specified in six cases.
†Differences between groups: χ2=6.3; p=0.043.
AF, atrial fibrillation.
Figure 3 Distribution on antiplatelet treatment within 
each category of anticoagulation status (group differences: 
χ2=145.3, p<0.001).
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or confidence of community clinicians to prescribe to 
patients whom they consider to be at high risk of potential 
side-effects. Lip et al studied 2634 patients and observed 
that 60.6% (1602) adhered to guideline for antithrom-
botic therapy, 17.3% (458) were undertreated and 21.7% 
(574) overtreated. Those who did not adhere to guide-
line were significantly more common among the elderly 
(≥75 years) and females. Patients who were detected for 
the first time or had paroxysmal AF were significantly 
more likely to be undertreated.31 Lip et al also found that 
treatment for lone AF tended not to be adhered to guide-
lines.31 To improve the identification of AF, particularly 
among those with high risk or low awareness of the condi-
tion, routine ECG screening should be implemented. 
Holter ECG monitoring over 48–72 hours on discharge 
is routinely performed for patients with thromboembolic 
stroke but may still miss those with paroxysmal AF. There 
are devices designed for long period of monitoring such 
as ‘Reveal Device’, but this technique is invasive and 
costly. New devices such as hand held devices designed 
to record cardiac rhythm over a period up to 4 weeks are 
being evaluated.32
Conclusion
The study highlights an existing burden for patients with 
stroke in the County of Surrey and reflects inadequate 
treatment of AF which is associated with increased risk of 
stroke. There is significant scope to improve the rates of 
anticoagulation and this is evident through the analysis 
which demonstrates a high proportion of anticoagulation 
in previously anticoagulation naïve and also higher risk 
patients.
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